|
|
|
Underlying diseases |
Age |
|
|
Zhou-202013
|
Retrospective cohort study |
Linezolid |
Acute myeloid leukaemia (AML) and bacterial infection |
45.8 ± 13.6 |
36 |
≥ 7 |
|
|
Vancomycin |
|
47.2 ± 13.1 |
41 |
|
Nalini-200414
|
Retrospective cohort study |
Linezolid |
Gram-positive bacterial
orthopedic
infections
|
NM |
20 |
Mean 71 |
|
|
Vancomycin |
|
NM |
52 |
Mean 42 |
Stanley-200315
|
Retrospective cohort study |
Linezolid |
Nosocomial pneumonia |
58.7% ≥65 |
356 |
Mean
10.7±4.4 |
|
|
Vancomycin |
|
51.9% ≥65 |
330 |
Mean 10.5±3.7 |
Nimish-201216
|
Retrospective cohort study |
Linezolid |
Bacterial infection |
68.5 ± 12.4 |
251 |
Mean 10 |
|
|
Vancomycin |
|
68.6 ± 13.3 |
251 |
Mean 7 |
Satoshi-201317
|
Retrospective cohort study |
Linezolid |
Severe infections |
68.0±15.4 |
91 |
7.0±5.8 |
|
|
Vancomycin |
|
64.0±14.1 |
160 |
10.0±11.4 |
Daniel-201118
|
Cross-sectional study |
Vancomycin |
Bacterial infection |
50.6 |
98 |
9.7(95%CI: 8.0-11.7) |